This could really lift your spirits.
A fascinating new study suggests that widely used medications, typically prescribed for improving mood, might also have a role in combating cancer.
“These drugs have been safely utilized for treating depression for many years, so repurposing them for cancer is more straightforward than developing a completely new treatment,” I mentioned in a press release.
Researchers led by Yang found that selective serotonin reuptake inhibitors (SSRIs)—like Prozac and Celexa, which millions of Americans take daily—can enhance T cell functionality against tumors.
“SSRIs don’t just boost our mood; they also support T cells,” she explained.
In laboratory tests involving both mouse and human tumor models (covering various types, including breast, prostate, colon, and bladder cancers), SSRIs led to a tumor reduction of over 50%.
This medication significantly increased the activity of killer T cells, empowering them to locate and destroy cancer cells.
“SSRIs improved killer T cell performance in challenging tumor environments by enhancing serotonin signaling and reactivating them to combat cancer,” Yang noted.
Serotonin is best known for its role in mood regulation, but it also influences sleep, gut health, appetite, libido, and blood clotting.
Now, it seems, we might harness it to fight this serious illness.
The study findings, published in the Journal Cell, hold promise as SSRIs are already FDA-approved, setting the stage for clinical trials. This could lead to exciting advancements in cancer therapies.
“Creating a new cancer treatment from scratch typically costs around $1.5 billion,” she added.
“In contrast, reusing FDA-approved drugs may only require about $300 million, highlighting why this strategy has gained popularity.”
But wait, there’s more.
When SSRIs are used alongside existing cancer immunotherapies, the outcomes are even more remarkable.
In treated mice, tumors show significant shrinkage, with some even vanishing entirely.
“Immune checkpoint blockades are only effective in fewer than 25% of patients,” stated James Ersten Brown, a graduate student at Jan Lab.
“If safe and widely accessible drugs like SSRIs can enhance these treatments’ effectiveness, it could be incredibly impactful.”
